J. Antonio G. Lopez, MD, FACC, FAHA, FNLA, FASPC (@jantonioglopezmd.bsky.social)

Registry data point to ‘striking shift’ in treatment decisions after FDA approved low-risk TAVR Many experts still recommend SAVR over TAVR for patients younger than 65 years old with severe aortic stenosis. However, transcatheter treatments are growing more and more popular when these younger p... https://cardiovascularbusiness.com/topics/clinical/structural-heart-disease/tavr/registry-data-point-striking-shift-treatment-decisions-after-fda-approved-low-risk-tavr